Paolo Tarantino, Clinical Research Fellow at Dana-Farber Cancer Institute, shared on X:
“Reminds me of TOPO1 ADCs in metastatic breast cancer.
- T-DXd
- Dato-DXd
- HER3-DXd
- B7H3 ADCs (eg SYS6043)
- EGFR/HER3 ADC (eg Iza Bren)
All with 40-60% ORR (slight differences depending on setting and disease subtype).
Payload sensitivity – target relevance.”
This also can be interesting:
